CAR-engineered NK cells
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About Glycostem
Glycostem Therapeutics is a pioneering developer of allogeneic, off-the-shelf NK cell immunotherapies derived from umbilical cord blood stem cells. Its core technology platform enables the production of highly pure, safe, and cost-effective NK cell products, with a lead candidate, oNKord®, in a pivotal Phase I/IIa trial for AML. The company has established a strategic partnership with medac GmbH for commercialization and is expanding its pipeline to include next-generation CAR-NK and other engineered NK cell therapies targeting both hematological and solid tumors.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |